title: The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro.
abstract: Cannabidiol is the main nonpsychoactive component of marijuana. We examined the ability of in vivo and in vitro cannabidiol to interfere with the production of interleukin (IL)-12 and IL-10 by murine macrophages and to modulate macrophage chemotaxis. Cannabidiol added in vitro to peritoneal macrophages significantly increased IL-12 and decreased IL-10 production. The CB1 and CB2 receptor antagonists prevented this modulation. Macrophages from animals treated with cannabidiol at the dose of 30 mg kg(-1) either orally or i.p. produced higher levels of IL-12 and lower levels of IL-10 in comparison to controls, and the CB receptor antagonists did not prevent these effects. Cannabidiol dose-dependently decreased fMLP-induced chemotaxis of macrophages, and the CB2 receptor antagonist prevented this decrease.
authors.affiliation: Department of Pharmacology, via Vanvitelli 32, 20129 Milano, Italy. paola.sacerdote@unimi.it
authors.forename: P
authors.initials: P
authors.lastname: Sacerdote
authors.forename: C
authors.initials: C
authors.lastname: Martucci
authors.forename: A
authors.initials: A
authors.lastname: Vaccani
authors.forename: F
authors.initials: F
authors.lastname: Bariselli
authors.forename: A E
authors.initials: AE
authors.lastname: Panerai
authors.forename: A
authors.initials: A
authors.lastname: Colombo
authors.forename: D
authors.initials: D
authors.lastname: Parolaro
authors.forename: P
authors.initials: P
authors.lastname: Massi
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D001892:Camphanes / Q000494:pharmacology; D002185:Cannabidiol / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D002464:Cell Migration Inhibition; D002478:Cells, Cultured; D002633:Chemotaxis / Q000187:drug effects* / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D016753:Interleukin-10 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D018664:Interleukin-12 / Q000096:biosynthesis*; D008262:Macrophage Activation / Q000187:drug effects / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000502:physiology; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000502:physiology; D000077285:Rimonabant; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D001892:Camphanes; D016207:Cytokines; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C110630:SR 144528; D016753:Interleukin-10; D018664:Interleukin-12; D002185:Cannabidiol; D000077285:Rimonabant